Search results
Results from the WOW.Com Content Network
Breastfeeding and medications is the description of the medications that can be used by a breastfeeding mother, and the balance between maternal health and the safety of the breastfeeding infant. [ 1 ] [ 2 ] Medications, when administered to breastfeeding mothers, almost always are transferred to breast milk, albeit usually in small quantities ...
Use during breastfeeding appears to be safe. [4] Paromomycin is in the aminoglycoside family of medications and causes microbe death by stopping the creation of bacterial proteins. [3] Paromomycin was discovered in the 1950s from a type of streptomyces and came into medical use in 1960.
The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl: 10665/259481. ISBN 978-92-4-121015-7. ISSN 0512-3054. WHO technical report series; no. 1006.
Contraindications to breastfeeding are those conditions that could compromise the health of the infant if breast milk from their mother is consumed. Examples include galactosemia , untreated HIV , untreated active tuberculosis , Human T-lymphotropic virus 1 or II , uses illicit drugs , or mothers undergoing chemotherapy or radiation treatment .
At two years from the first live birth, the proportion of women with breast cancer recurrence or new breast cancer was similar in those who breastfed (3.6%) and those who did not (3.1%).
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
It appears safe in breastfeeding. [11] Greater care is recommended in those with heart problems. [12] It is an anticholinergic agent, [5] which does not have much effect on the brain. [13] Hyoscine butylbromide was patented in 1950, and approved for medical use in 1951. [14] It is on the World Health Organization's List of Essential Medicines. [15]
There are concerns from animal studies that it may increase the risk of cancer but these concerns have not been found in human trials. [5] Nifurtimox is not recommended in pregnancy or in those with significant kidney or liver problems. [5] It is a type of nitrofuran. [5] Nifurtimox came into medication use in 1965. [5]